CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05298683
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:44.672101+00:00
Published At: 2022-03-28T00:00:00+00:00
Record Updated At: 2022-03-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma", "Renal Impairment", "Neoplasms, Plasma Cell", "Neoplasms by Histologic Type", "Neoplasms", "Paraproteinemias", "Blood Protein Disorders", "Hematologic Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-03-28"
protocolSection.identificationModule.nctId: "NCT05298683"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.